Edesa Biotech has priced its $25 million public offering, featuring shares, warrants and pre-funded warrants, drawing fresh market attention.

Edesa Biotech, Inc. has priced an underwritten Edesa Biotech public offering that is estimated to raise about $25 million in gross proceeds, as the company is looking for more financing to pursue research, development, production, and general corporate purposes. The offering involves 3,870,500 shares of common stock accompanied by warrants, and pre-funded warrants involving up to 675,000 common shares.

Offering Includes Shares and Warrants

The common share will be offered together with a warrant to purchase another common share at a cost of $5.50. The warrants associated with the issue have a cost of exercise of $7.50 per share, and they are exercisable right from the time of issuance. The warrants will lapse on the earlier of either 18 months from issuance or 30 days from when Edesa announces its phase two topline data for EB06.

However, when the pre-funded warrants will be acquired by the investor, the total price is equal to $5.4999 per share, but the exercise price for the pre-funded warrants is $0.0001. Moreover, Edesa has given an option to underwriters to buy additional 681,825 common shares and their warrants at the public offering price within 30 days.

Key details of the Edesa Biotech public offering:

  • Edesa expects approximately $25 million in gross proceeds.

  • Common shares and warrants are priced at $5.50.

  • Common share warrants carry a $7.50 exercise price.

  • Pre-funded warrants have a $0.0001 exercise price.

  • Offering closure is expected around August 21, 2026.

Funding to Support Clinical Development

Edesa plans to direct the net proceeds toward general corporate purposes, potentially including working capital, capital expenditures, research and development, and manufacturing expenses. The financing comes as the company continues developing host-directed therapeutics for immuno-inflammatory diseases, including its vitiligo program and EB06.

The Edesa Biotech financing is being conducted under a shelf registration statement on Form S-3 that became effective with the U.S. Securities and Exchange Commission in September 2025. The preliminary prospectus supplement has been filed, while final offering terms are expected to be provided through a final prospectus supplement.aGuggenheim Securities is serving as the sole book-running manager. The offering is expected to close on or about August 21, 2026, subject to customary closing conditions.

Business Fortune is of the view that Edesa Biotech’s financing strengthens its resources to advance clinical programs and support future growth initiatives.

 

FAQs

How much does Edesa Biotech expect to raise from the public offering?

Edesa Biotech expects the underwritten public offering to generate approximately $25 million in gross proceeds.

What securities are included in the Edesa Biotech offering?

The offering includes 3,870,500 common shares accompanied by warrants, along with pre-funded warrants covering up to 675,000 common shares.

What are the exercise prices of the warrants?

The warrants accompanying common shares have an exercise price of $7.50 per share. The pre-funded warrants have an exercise price of $0.0001 per share.

How will Edesa Biotech use the offering proceeds?

Edesa plans to use the net proceeds for general corporate purposes, including working capital, research and development, manufacturing expenses, and capital expenditures.

When is the Edesa Biotech offering expected to close?

The offering is expected to close on or about August 21, 2026, subject to customary closing conditions. Guggenheim Securities is serving as the sole book-running manager.